🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. Azenosertib

    Zentalis Pharmaceuticals

    Uterine Serous Carcinoma

    phase 2 small molecule active

    2 trials

  2. BAX69 Single-Route Arm

    Takeda

    Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites

    phase 2 mab terminated

    1 trial

  3. BB-401

    Benitec Biopharma

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  4. BBI608

    Sumitomo Pharma (Suzhou) Co.,

    Malignant Pleural Mesothelioma

    phase 2 small molecule completed

    1 trial

  5. BCG-MEDAC, poudre et solvant pour suspension intravésicale, PD1IL2v iMAb

    Hoffmann-La Roche

    BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)

    phase 2 small molecule active

    1 trial

  6. BCT197

    Mereo BioPharma Group plc

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  7. BCT197

    Mereo BioPharma Group plc

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  8. BCT197 Part A

    Mereo BioPharma Group plc

    Acute Kidney Injury

    phase 2 small molecule terminated

    1 trial

  9. BEVACIZUMAB, IRINOTECAN, FOLINIC ACID, Telisotuzumab adizutecan, FLUOROURACIL

    AbbVie Deutschland GmbH & Co. KG

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  10. BGB-11417, Zanubrutinib, BGB-11417, BGB-11417, BGB-11417

    BEONE MEDICINES AUS PTY LTD

    previously untreated chronic lymphocytic leukemia (CLL)

    phase 2 small molecule active

    1 trial

  11. BGB-11417, Zanubrutinib, BGB-11417, BGB-11417, BGB-11417

    BEONE MEDICINES AUS PTY LTD

    Previously Untreated Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  12. BGS649

    Mereo BioPharma Group plc

    Hypogonadotropic Hypogonadism

    phase 2 small molecule completed

    2 trials

  13. BGS649

    Mereo BioPharma Group plc

    Pelvic Pain Associated With Refractory Endometriosis

    phase 2 small molecule terminated

    1 trial

  14. BI 1810631

    Boehringer Ingelheim

    HER2-mutated or overexpressed/amplified solid tumours

    phase 2 small molecule active

    1 trial

  15. BI 1819479, Placebo, Film-coated tablet, matching in size, weight, colour and shape to BI 1819479 (both unit strengths), BI 1819479

    Boehringer Ingelheim

    idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  16. BI 1839100, Placebo matching in size, weight, colour and shape to tablets of BI 1839100

    Boehringer Ingelheim

    Progressive pulmonary fibrosis (PPF), Idiopathic pulmonary fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  17. BI 907828, BI 907828, BI 907828

    Boehringer Ingelheim

    Solid tumours

    phase 2 small molecule active

    1 trial

  18. BI-754091 plus afatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 2 small molecule completed

    1 trial

  19. BLEOMYCIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, VINBLASTINE , CYCLOPHOSPHAMIDE , ETOPOSIDE , DACARBAZINE , PREDNISOLONE, VINCRISTINE , PREDNISONE, DOXORUBICIN

    Merck Sharp and Dohme

    Classical Hodgkin lymphoma in children and young adults

    phase 2 small molecule active

    1 trial

  20. BLEOMYCIN, CISPLATIN

    Fondazione Telethon ETS

    patients with newly diagnosed or recurrent high-grade or initially invasive precancerous squamous lesions of the vulva and non-invasive vulvar Paget's disease

    phase 2 small molecule active

    1 trial

  21. BLEOPRIM 15 mg polvere per soluzione iniettabile, Fluorouracil 50 mg/ml Solution for Injection or Infusion, LEDERFOLIN 25 mg Polvere per soluzione iniettabile per uso endovenoso, CAMPTO 20 mg/mL concentrate for solution for infusion, Oxaliplatin 5 mg/ml Concentrate for Solution for infusion

    Fondazione Telethon ETS

    Locally Advanced Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  22. BLEOPRIM 15 mg polvere per soluzione iniettabile, Fluorouracile Teva 250 mg/5 ml soluzione per infusione, CARBOPLATINO TEVA 10 mg/ml concentrato per soluzione per infusione, CETUXIMAB, PEMBROLIZUMAB, Cisplatino Teva Italia 0,5 mg/ml concentrato per soluzione per infusione

    Fondazione Telethon ETS

    CARCINOMA OF THE ORAL CAVITY AND OROPHARYNX

    phase 2 small molecule active

    1 trial

  23. BMS-986165

    Bristol-Myers Squibb

    Granulomatous Colitis

    phase 2 small molecule terminated

    1 trial

  24. BOTULINUM TOXIN , -

    The George Institute

    Myogenous temporomandibular disorders (TMDM)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources